Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
Protagonist Therapeutics (PTGX) Stock Price & Analysis
487 Followers
PTGX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.91 - $25.76
Previous Close$22.34
Volume257.99K
Average Volume (3M)1.67M
Market Cap
$1.14B
Enterprise Value$911.79M
Total Cash (Recent Filing)$237.35M
Total Debt (Recent Filing)$3.66M
Price to Earnings (P/E)-8.6
Beta1.23
Next Earnings
May 10, 2023EPS Estimate
-$0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding51,275,166
10 Day Avg. Volume1,297,930
30 Day Avg. Volume1,667,111
Standard Deviation0.30
R-Squared0.13
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)4.93
Price to Sales (P/S)40.55
Price to Cash Flow (P/CF)39.50
P/FCF Ratio-9.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue34.30
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-7.35
Forecast
1Y Price Target
$34.50Price Target Upside54.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Protagonist Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PTGX FAQ
What was Protagonist Therapeutics’s price range in the past 12 months?
Protagonist Therapeutics lowest stock price was $6.91 and its highest was $25.76 in the past 12 months.
What is Protagonist Therapeutics’s market cap?
Currently, no data Available
When is Protagonist Therapeutics’s upcoming earnings report date?
Protagonist Therapeutics’s upcoming earnings report date is May 10, 2023 which is in 41 days.
How were Protagonist Therapeutics’s earnings last quarter?
Protagonist Therapeutics released its earnings results on Mar 15, 2023. The company reported -$0.69 earnings per share for the quarter, missing the consensus estimate of -$0.668 by -$0.022.
Is Protagonist Therapeutics overvalued?
According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued.
Does Protagonist Therapeutics pay dividends?
Protagonist Therapeutics does not currently pay dividends.
What is Protagonist Therapeutics’s EPS estimate?
Protagonist Therapeutics’s EPS estimate is -$0.73.
How many shares outstanding does Protagonist Therapeutics have?
Protagonist Therapeutics has 51,275,166 shares outstanding.
What happened to Protagonist Therapeutics’s price movement after its last earnings report?
Protagonist Therapeutics reported an EPS of -$0.69 in its last earnings report, missing expectations of -$0.668. Following the earnings report the stock price went down -3.742%.
Which hedge fund is a major shareholder of Protagonist Therapeutics?
Among the largest hedge funds holding Protagonist Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Protagonist Therapeutics’s shares valued at 40M.
---
Protagonist Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.50 (54.71% Upside)
$34.50 (54.71% Upside)
Blogger Sentiment
Bullish
PTGX Sentiment 66%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 480.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.99%
12-Months-Change
Fundamentals
Return on Equity
-49.41%
Trailing 12-Months
Asset Growth
-28.69%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Protagonist Therapeutics
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
---
Top 5 ETFs holding PTGX
Dimensional U.S. Equity ETF
$76.70K
Up to five ETFs with an Outperform Smart Score that hold PTGX. The ETFs are listed according to market value of PTGX within the ETF
---
C4 Therapeutics
―
Lexicon Pharmaceuticals
―
Poseida Therapeutics
―
Arbutus Biopharma
―
Kodiak Sciences
―
---